NANOVIRICIDES, INC.
NNVC · XNYSCIK 1379006fmd_12QRMQKXPQGZQS9DBCM1DTQXA7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2004 to Jun 30, 2026, 70 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Research and development | 7 | 6 | 6 | 5 | 6 | 6 | 6 | 5 | 6 | 5 |
| Total operating expenses | 10 | 9 | 9 | 8 | 9 | 8 | 9 | 9 | 10 | 8 |
| Operating income | (10) | (9) | (9) | (8) | (9) | (8) | (9) | (9) | (10) | (8) |
| Interest expense | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | 1 | 0 | (5) | (0) | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (10) | (9) | (8) | (13) | (9) | (8) | – | – | – | (8) |
| Income tax expense | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Net income from continuing operations | (10) | (9) | (8) | (13) | – | – | – | – | – | – |
| Net income | (10) | (9) | (8) | (13) | (9) | (8) | (9) | (8) | (9) | (8) |
| Net income to common shareholders | (10) | (9) | – | – | – | – | – | – | – | – |